Helicobacter pylori infection is a major cause of morbidity and mortality worldwide and infection invariably causes active chronic gastritis. In many people this may be clinically silent throughout life, but in a significant minority it results in gastroduodenal diseases, especially peptic ulcer disease, non-cardia gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
The major determinant of successful eradication is the presence or absence of pre-treatment antimicrobial resistance. In Australia, three evidence-based options for second-line therapy have been evaluated and are presented in this article from this recent issue of the
Medical Journal of Australia.
No comments:
Post a Comment